Novo Nordisk Slaps HIMS With Lawsuit Over Copycat Wegovy Pill As GLP-1 Feud Erupts

The GLP-1 feud between Hims & Hers Health and Novo Nordisk keeps accelerating by the day.

HIMS rejected again trying to make a criminal racket into a business model https://t.co/URBLu257l8

— zerohedge (@zerohedge) February 6, 2026

The latest is that Novo is now taking legal action against HIMS, alleging that the telehealth firm “unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at risk.”

In late January, Novo released a $149 per month Wegovy pill, with HIMS just days later releasing a GLP-1 copycat pill of Wegovy for $49 a month.

By late last week, FDA Commissioner Marty Makary warned against companies “mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products.”

FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products.

The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.

— Dr. Marty Makary (@DrMakaryFDA) February 5, 2026

Then, on Saturday, not even a day after Makary’s comments, HIMS pulled the GLP-1 copycat pill …

*HIMS & HERS TO STOP OFFERING WEIGHT LOSS PILL https://t.co/tiQoqBHf0K

— zerohedge (@zerohedge) February 7, 2026

Back to Novo’s lawsuit.

Here are the three takeaways:

Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at risk

Novo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetes

Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages

“Hims & Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process – that’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective,” John F. Kuckelman, senior vice president, Group General Counsel, Global Legal, IP and Security, wrote in a statement.

Kuckelman noted, “We’ve taken legal action to protect the American public and our intellectual property and will continue to work with regulators, law enforcement, and other key stakeholders to ensure patients have access to FDA-approved safe and effective medicines.”

In markets, HIMS shares fell 20% in New York premarket trading after its GLP-1 copycat pill was pulled, with additional pressure from Novo’s lawsuit.

On the other hand, Novo Shares in Denmark moved up 7%. Shares were beaten down last week amid a dismal full-year earnings outlook and HIMS’ GLP-1 copycat pill.

Here’s our coverage on the HIMS-Novo feud:

“Much-Needed Win”: Novo Shares Jump Most In Nearly Two Years After US Approval Of Wegovy Obesity Pill

“Big Miss”: Wall Street Disappointed After Dismal Novo Nordisk GLP-1 Sales Outlook, Shares Plunge

$49 Wegovy Copycat Pill Sparks Selloff In Novo Shares

HIMS Halts Copycat GLP-1 Pill After FDA Warns Of “Swift Action”

Citi analyst Daniel Grosslight told clients that the FDA’s crackdown on HIMS’ “aggressive compounding practices” suggests there could be further downside if the FDA “completely eliminates or severely curtails” HIMS’ ability to compound GLP-1s. He rates the stock “Sell” and slashed his price target to $16.50 from $30.